Velarion · Company Intelligence
Compensation Brief
Fiscal year 2023 · Filings through 2026-04-08

IGM Biosciences (IGMS)

CEO Fred Schwarzer was paid $3,207,328 in fiscal year 2023, ↓ down 39.7% from fiscal year 2022, the 1st percentile of its disclosed peer group (SEC filing 0000950170-24-049091 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$3,207,328 ↓
Fred Schwarzer total, FY2023
1st
CEO pay percentile vs peers
—
CEO-to-median pay ratio
—
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Fred Schwarzer (Chief Executive Officer, President and Director), FY2023 total compensation $3,207,328 (base salary $646,797) [exec_comp, SEC accession 0000950170-24-049091, filed 2024-04-26]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

01

Summary Compensation Table — fiscal year 2023

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Fred Schwarzer$646,797$0$868,050$1,336,743$355,738$0$0$3,207,328
Chief Executive Officer, President and Director
Bruce Keyt492,3260337,575519,845221,458001,571,204
Chief Scientific Officer
Chris Takimoto486,4920337,575519,845218,900001,562,812
Chief Medical Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2023 totalFY2022 totalFY2021 totalΔ FY2022→2023
Fred Schwarzer$3,207,328$5,316,460—↓ −2,109,132
Bruce Keyt1,571,2041,839,300—↓ −268,096
Chris Takimoto1,562,8121,827,118—↓ −264,306

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read IGM Biosciences's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper IGMS reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against IGMS
14 companies name IGMS as a compensation peer

Each company listed discloses IGMS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named IGMS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2023 total
Bruce KeytChief Scientific Officer$1,571,204
Chris TakimotoChief Medical Officer$1,562,812
Fred SchwarzerCEO$3,207,328
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2023 total
Christina Teng TopsoeDirector—
Elizabeth H.Z. ThompsonIndependent Director$167,535
Felix J. BakerIndependent Director$168,549
Jakob Haldor TopsoeDirector—
Julie HambletonIndependent Director$204,094
M. Kathleen BehrensIndependent Director$178,298
Michael LeeIndependent Director$166,092
Michael LobergFormer director (through FY2023)$182,544
William StrohlIndependent Director$236,594
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
BAKER BROS. ADVISORS LPDirector2024-12-31A1,994$0$0CommonForm 4 ↗
Redmile Group, LLCDirector2024-12-31A1,73400Common, indirectForm 4 ↗
Christina Teng TopsoeDirector2024-12-31A2,68700CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2024-12-31A1,99400CommonForm 4 ↗
M. Kathleen BehrensDirector2024-12-31A3,07800CommonForm 4 ↗
Michael LeeDirector2024-12-31A1,73400Common, indirectForm 4 ↗
Jakob Haldor TopsoeDirector2024-12-31A1,73400CommonForm 4 ↗
Elizabeth H.Z. ThompsonDirector2024-12-31A1,45200CommonForm 4 ↗
Steven WeberPRINCIPAL ACCOUNTING OFFICER2025-01-15D1,12221,907Common, open-market saleForm 4 ↗
Misbah TahirCHIEF FINANCIAL OFFICER2025-03-14D7,32919,015Common, open-market saleForm 4 ↗
Lisa Lynn DeckerCHIEF BUSINESS OFFICER2025-03-14D4,51215,550Common, open-market saleForm 4 ↗
Mary Beth HarlerDirector2025-03-14D7,32919,015Common, open-market saleForm 4 ↗
Steven WeberPRINCIPAL ACCOUNTING OFFICER2025-03-14D1,70112,092Common, open-market saleForm 4 ↗
Christina Teng TopsoeDirector2025-03-31A1,28400CommonForm 4 ↗
Jakob Haldor TopsoeDirector2025-03-31A82800CommonForm 4 ↗
Elizabeth H.Z. ThompsonDirector2025-03-31A69400CommonForm 4 ↗
Michael LeeDirector2025-03-31A82800Common, indirectForm 4 ↗
BAKER BROS. ADVISORS LPDirector2025-03-31A95300CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2025-03-31A95300CommonForm 4 ↗
Redmile Group, LLCDirector2025-03-31A82800Common, indirectForm 4 ↗
M. Kathleen BehrensDirector2025-03-31A1,47100CommonForm 4 ↗
Steven WeberPRINCIPAL ACCOUNTING OFFICER2025-05-14D1,86512,090Common, open-market saleForm 4 ↗
Steven WeberPRINCIPAL ACCOUNTING OFFICER2025-06-16D4861583Common, open-market saleForm 4 ↗
Lisa Lynn DeckerCHIEF BUSINESS OFFICER2025-06-16D95111,140Common, open-market saleForm 4 ↗
Mary Beth HarlerDirector2025-06-16D1,52211,825Common, open-market saleForm 4 ↗
Misbah TahirCHIEF FINANCIAL OFFICER2025-06-16D1,52211,825Common, open-market saleForm 4 ↗
Christina Teng TopsoeDirector2025-06-30A1,28400CommonForm 4 ↗
Redmile Group, LLCDirector2025-06-30A82800Common, indirectForm 4 ↗
BAKER BROS. ADVISORS LPDirector2025-06-30A95300CommonForm 4 ↗
Michael LeeDirector2025-06-30A82800Common, indirectForm 4 ↗
BAKER BROS. ADVISORS LPDirector2025-06-30A95300CommonForm 4 ↗
M. Kathleen BehrensDirector2025-06-30A1,47100CommonForm 4 ↗
Elizabeth H.Z. ThompsonDirector2025-06-30A69400CommonForm 4 ↗
Jakob Haldor TopsoeDirector2025-06-30A82800CommonForm 4 ↗
Misbah TahirCHIEF FINANCIAL OFFICER2025-07-23D8,741111,126Common, open-market saleForm 4 ↗
Mary Beth HarlerDirector2025-07-23D14,501118,457Common, open-market saleForm 4 ↗
Lisa Lynn DeckerCHIEF BUSINESS OFFICER2025-07-23D4,40915,612Common, open-market saleForm 4 ↗
Redmile Group, LLCDirector2025-08-14D2,964,843——CommonForm 4 ↗
M. Kathleen BehrensDirector2025-08-14D22,222——CommonForm 4 ↗
William StrohlDirector2025-08-14D125,000——CommonForm 4 ↗
Elizabeth H.Z. ThompsonDirector2025-08-14D7,196——CommonForm 4 ↗
M. Kathleen BehrensDirector2025-08-14D330,700——CommonForm 4 ↗
Mary Beth HarlerDirector2025-08-14D323,680——CommonForm 4 ↗
Jakob Haldor TopsoeDirector2025-08-14D5,044,29500Derivative, Class A CommonForm 4 ↗
Jakob Haldor TopsoeDirector2025-08-14D91,712——CommonForm 4 ↗
Holding A/S TopsoeGreater-than-10% holder2025-08-14D5,044,29500Derivative, Class A CommonForm 4 ↗
Michael LeeDirector2025-08-14D12,712——CommonForm 4 ↗
Julie HambletonDirector2025-08-14D2,000——CommonForm 4 ↗
Redmile Group, LLCDirector2025-08-14D7,199,325——Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LP—2025-08-14D9,886,21700Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LP—2025-08-14D3,763,362——CommonForm 4 ↗
BAKER BROS. ADVISORS LP—2025-08-14D357,048——CommonForm 4 ↗
M. Kathleen BehrensDirector2025-08-14D29,806——CommonForm 4 ↗
M. Kathleen BehrensDirector2025-08-14D29,807——CommonForm 4 ↗
Jakob Haldor TopsoeDirector2025-08-14D10,400,564——CommonForm 4 ↗
Holding A/S TopsoeGreater-than-10% holder2025-08-14D10,400,564——CommonForm 4 ↗
Christina Teng TopsoeDirector2025-08-14D9,800——CommonForm 4 ↗
Redmile Group, LLCDirector2025-08-14D667,666——Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LP—2025-08-14D834,70700Derivative, Class A CommonForm 4 ↗
Christina Teng TopsoeDirector2025-08-14D5,044,29500Derivative, Class A CommonForm 4 ↗
Christina Teng TopsoeDirector2025-08-14D54,235——CommonForm 4 ↗
Christina Teng TopsoeDirector2025-08-14D10,400,564——CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2023

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Fred SchwarzerRSU—————$868,050
Bruce KeytOPTION—————519,845
Chris TakimotoOPTION—————519,845
Chris TakimotoRSU—————337,575
Fred SchwarzerOPTION—————1,336,743
Bruce KeytRSU—————337,575
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Fred Schwarzer$868,050$0$1,336,7430.0%
Bruce Keyt337,5750519,8450.0%
Chris Takimoto337,5750519,8450.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2023

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Bruce KeytOption42,18817.11—
Chris TakimotoOption59,37568.01—
Fred SchwarzerRSU67,500—560,925
Fred SchwarzerOption109,68812.86—
Bruce KeytOption42,65712.86—
Bruce KeytRSU26,250—218,138
Chris TakimotoRSU26,250—218,138
Fred SchwarzerOption196,87517.11—
Fred SchwarzerOption6,25040.27—
Bruce KeytOption14,58491.5—
Bruce KeytOption3,12540.27—
Bruce KeytRSU9,375—77,906
Chris TakimotoRSU9,375—77,906
Fred SchwarzerOption36,45991.5—
Chris TakimotoOption42,18817.11—
Chris TakimotoOption42,65712.86—
05

Incentive-plan design — the Compensation Discussion & Analysis

The company aims to ensure that the compensation offered to executive officers is competitive and fair by using a peer group to determine appropriate levels. The compensation committee evaluates total compensation based on company results, individual contributions, and performance toward individual goal achievement.

CEO STI target (% of salary)55%
CEO LTI target (% of salary)—
Independent consultantAon
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingfalse
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20242024-06-11—————
20232023-06-23—————
20222022-06-21—————
20212021-06-24—————
20202020-07-30—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20242024-06-11—a
20232023-06-23—b
20222022-06-21—c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2023

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
William StrohlIndependent · Research and Clinical Development (Co-Chair)$90,000$0$146,594——$236,594
Julie HambletonIndependent · Audit · Research and Clinical Development (Co-Chair)57,5000146,594——204,094
Michael LobergIndependent · Not standing for re-election · Departed during FY035,950146,594——182,544
M. Kathleen BehrensIndependent · Audit (Chair) · Compensation · Nominating/Governance031,704146,594——178,298
Felix J. BakerIndependent · Research and Clinical Development021,955146,594——168,549
Elizabeth H.Z. ThompsonIndependent · Audit · Compensation · Nominating/Governance · Research and Clinical Development15,2850152,250——167,535
Michael LeeIndependent019,498146,594——166,092
Fred SchwarzerEmployee director—————0
Jakob Haldor Topsoe0—————
Christina Teng Topsoe0—————
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)15,000 / 10,000 / 10,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2023
Cash retainers and fees$162,785
Equity awards (grant-date value)$109,107
All other compensation$0
Total cost of the board$271,892

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2023

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies IGM Biosciences names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including IGM Biosciences.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Gilead Sciences2025Daniel O'Day$1,795,192$15,238,402$4,500,060$4,848,120$28,437,198
2Pfizer2025Albert Bourla1,800,0009,442,7058,998,1415,400,00027,585,301
3Bristol-Myers Squibb2025Christopher Boerner1,586,34616,061,39903,754,68421,879,919
4Merck & Co.2025Robert Davis1,645,30212,102,8383,380,0042,326,50020,797,845
5IGM Biosciences2023Fred Schwarzer646,797868,0501,336,743355,7383,207,328
—AstraZeneca——————not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
IGM Biosciencesnot disclosednot disclosednot disclosedAon
AstraZenecanot disclosednot disclosednot disclosednot disclosed
Bristol-Myers Squibb157.66%PSU 60 · MSU 40Yes — 3-Year Relative TSR CAGRFarient Advisors LLC
Gilead Sciences180%PSU 50 · Options 25 · RSU 25Yes — Relative TSRFW Cook
Merck & Co.94%PSU 60 · RSU 20 · Options 20Yes — Relative Total Shareholder Return (R-TSR)FW Cook
Pfizer150%PSU 50 · MSU 50Yes — relative TSR as compared to the NYSE Arca Pharmaceutical Index (DRG Index or DRG)Meridian Compensation Partners, LLC

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at IGM Biosciences in fiscal 2023?
As disclosed, Fred Schwarzer (Chief Executive Officer, President and Director) was the highest-paid executive at IGM Biosciences in fiscal 2023, with total compensation of $3,207,328.
How does IGM Biosciences's chief executive pay compare to its disclosed peer group?
As disclosed, Fred Schwarzer's total compensation ranked at the 1st percentile of IGM Biosciences's disclosed peer group.
How much does IGM Biosciences spend in total on board compensation for fiscal 2023?
As disclosed, IGM Biosciences reported total board compensation of $271,892 for fiscal 2023.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Fred SchwarzerDEF 14A2024-04-260000950170-24-049091Section “Summary Compensation Table” · page 34. As printed: 3,207,328. Filing ↗machine: r2 · c21 · span 824822–824831
2Section 01, Bruce KeytDEF 14A2024-04-260000950170-24-049091Section “Summary Compensation Table” · page 34. As printed: 1,571,204. Filing ↗machine: r4 · c21 · span 837011–837020
3Section 01, Chris TakimotoDEF 14A2024-04-260000950170-24-049091Section “Summary Compensation Table” · page 34. As printed: 1,562,812. Filing ↗
4Section 03, Fred Schwarzer RSUDEF 14A2024-04-260000950170-24-049091Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t15 · r2 · c9 · span 821748–821755
5Section 03, Bruce Keyt OPTIONDEF 14A2024-04-260000950170-24-049091Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t15 · r4 · c13 · span 834963–834970
6Section 03, Chris Takimoto OPTIONDEF 14A2024-04-260000950170-24-049091Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t15 · r6 · c13 · span 847131–847138
7Section 03, Chris Takimoto RSUDEF 14A2024-04-260000950170-24-049091Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t15 · r6 · c9 · span 846107–846114
8Section 03, Fred Schwarzer OPTIONDEF 14A2024-04-260000950170-24-049091Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t15 · r2 · c13 · span 822772–822781
9Section 03, Bruce Keyt RSUDEF 14A2024-04-260000950170-24-049091Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t15 · r4 · c9 · span 833939–833946
10Section 08, William StrohlDEF 14A2024-04-260000950170-24-049091Section “Director Compensation”. As printed: 236,594. Filing ↗machine: span 396597–396806
11Section 08, Julie HambletonDEF 14A2024-04-260000950170-24-049091Section “Director Compensation”. As printed: 204,094. Filing ↗machine: span 383049–383258
12Section 08, Michael LobergDEF 14A2024-04-260000950170-24-049091Section “Director Compensation”. As printed: 182,544. Filing ↗machine: span 392131–392340
13Section 08, M. Kathleen BehrensDEF 14A2024-04-260000950170-24-049091Section “Director Compensation”. As printed: 178,298. Filing ↗machine: span 378583–378792
14Section 08, Felix J. BakerDEF 14A2024-04-260000950170-24-049091Section “Director Compensation”. As printed: 168,549. Filing ↗machine: span 374112–374321
15Section 08, Elizabeth H.Z. ThompsonDEF 14A2024-04-260000950170-24-049091Section “Director Compensation”. As printed: 167,535. Filing ↗machine: span 401232–401441
16Section 08, Michael LeeDEF 14A2024-04-260000950170-24-049091Section “Director Compensation”. As printed: 166,092. Filing ↗machine: span 387505–387714
17Section 08, Fred SchwarzerDEF 14A2024-04-260000950170-24-049091Section “Director Compensation”. As printed: 0. Filing ↗
18Section 08, Jakob Haldor TopsoeDEF 14A2024-04-260000950170-24-049091Section “Director Compensation”. As printed: —. Filing ↗
19Section 08, Christina Teng TopsoeDEF 14A2024-04-260000950170-24-049091Section “Director Compensation”. As printed: —. Filing ↗
20Section 02, BAKER BROS. ADVISORS LP 2024-12-31Form 42025-01-030000950170-25-001362Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Redmile Group, LLC 2024-12-31Form 42025-01-020001104659-25-000432Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Christina Teng Topsoe 2024-12-31Form 42025-01-030001415889-25-000610Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, BAKER BROS. ADVISORS LP 2024-12-31Form 42025-01-030000950170-25-001362Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, M. Kathleen Behrens 2024-12-31Form 42025-01-030001415889-25-000608Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Michael Lee 2024-12-31Form 42025-01-020001104659-25-000434Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Jakob Haldor Topsoe 2024-12-31Form 42025-01-030001415889-25-000611Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Elizabeth H.Z. Thompson 2024-12-31Form 42025-01-030001415889-25-000609Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Steven Weber 2025-01-15Form 42025-01-170001415889-25-001715Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Misbah Tahir 2025-03-14Form 42025-03-180001415889-25-008520Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Lisa Lynn Decker 2025-03-14Form 42025-03-180001415889-25-008518Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Mary Beth Harler 2025-03-14Form 42025-03-180001415889-25-008519Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Steven Weber 2025-03-14Form 42025-03-180001415889-25-008521Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Christina Teng Topsoe 2025-03-31Form 42025-04-020001415889-25-009779Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Jakob Haldor Topsoe 2025-03-31Form 42025-04-020001415889-25-009780Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Elizabeth H.Z. Thompson 2025-03-31Form 42025-04-020001415889-25-009778Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Michael Lee 2025-03-31Form 42025-04-020001104659-25-031355Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, BAKER BROS. ADVISORS LP 2025-03-31Form 42025-04-020000950170-25-049450Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, BAKER BROS. ADVISORS LP 2025-03-31Form 42025-04-020000950170-25-049450Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Redmile Group, LLC 2025-03-31Form 42025-04-020001104659-25-031353Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, M. Kathleen Behrens 2025-03-31Form 42025-04-020001415889-25-009777Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Steven Weber 2025-05-14Form 42025-05-160001415889-25-013410Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Steven Weber 2025-06-16Form 42025-06-200001415889-25-017916Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Lisa Lynn Decker 2025-06-16Form 42025-06-200001415889-25-017911Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Mary Beth Harler 2025-06-16Form 42025-06-200001415889-25-017913Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Misbah Tahir 2025-06-16Form 42025-06-200001415889-25-017915Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Christina Teng Topsoe 2025-06-30Form 42025-07-020001415889-25-019154Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Redmile Group, LLC 2025-06-30Form 42025-07-020001104659-25-065256Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, BAKER BROS. ADVISORS LP 2025-06-30Form 42025-07-020000950170-25-093254Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Michael Lee 2025-06-30Form 42025-07-020001104659-25-065262Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, BAKER BROS. ADVISORS LP 2025-06-30Form 42025-07-020000950170-25-093254Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, M. Kathleen Behrens 2025-06-30Form 42025-07-020001415889-25-019152Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Elizabeth H.Z. Thompson 2025-06-30Form 42025-07-020001415889-25-019153Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Jakob Haldor Topsoe 2025-06-30Form 42025-07-020001415889-25-019155Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Misbah Tahir 2025-07-23Form 42025-07-250001415889-25-020311Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Mary Beth Harler 2025-07-23Form 42025-07-250001415889-25-020310Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Lisa Lynn Decker 2025-07-23Form 42025-07-250001415889-25-020309Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Redmile Group, LLC 2025-08-14Form 42025-08-150001104659-25-079307Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, M. Kathleen Behrens 2025-08-14Form 42025-08-140001415889-25-021950Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, William Strohl 2025-08-14Form 42025-08-140001415889-25-021960Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Elizabeth H.Z. Thompson 2025-08-14Form 42025-08-140001415889-25-021961Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, M. Kathleen Behrens 2025-08-14Form 42025-08-140001415889-25-021950Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Mary Beth Harler 2025-08-14Form 42025-08-140001415889-25-021959Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Jakob Haldor Topsoe 2025-08-14Form 42025-08-140001415889-25-021970Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Jakob Haldor Topsoe 2025-08-14Form 42025-08-140001415889-25-021970Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Holding A/S Topsoe 2025-08-14Form 42025-08-140001415889-25-021975Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Michael Lee 2025-08-14Form 42025-08-140001104659-25-078832Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Julie Hambleton 2025-08-14Form 42025-08-140001415889-25-022042Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Redmile Group, LLC 2025-08-14Form 42025-08-150001104659-25-079307Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, BAKER BROS. ADVISORS LP 2025-08-14Form 42025-08-180000950170-25-109854Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, BAKER BROS. ADVISORS LP 2025-08-14Form 42025-08-180000950170-25-109854Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, BAKER BROS. ADVISORS LP 2025-08-14Form 42025-08-180000950170-25-109854Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, M. Kathleen Behrens 2025-08-14Form 42025-08-140001415889-25-021950Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, M. Kathleen Behrens 2025-08-14Form 42025-08-140001415889-25-021950Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Jakob Haldor Topsoe 2025-08-14Form 42025-08-140001415889-25-021970Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Holding A/S Topsoe 2025-08-14Form 42025-08-140001415889-25-021975Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Christina Teng Topsoe 2025-08-14Form 42025-08-140001415889-25-021964Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Redmile Group, LLC 2025-08-14Form 42025-08-150001104659-25-079307Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, BAKER BROS. ADVISORS LP 2025-08-14Form 42025-08-180000950170-25-109854Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Christina Teng Topsoe 2025-08-14Form 42025-08-140001415889-25-021964Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Christina Teng Topsoe 2025-08-14Form 42025-08-140001415889-25-021964Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Christina Teng Topsoe 2025-08-14Form 42025-08-140001415889-25-021964Insider equity transaction reported since the proxy statement. Filing ↗
82Section 06, 2024 voteForm 8-K2024-06-140000950170-24-073354Item 5.07 · say-on-pay result. As reported: —. Filing ↗
83Section 06, 2023 voteForm 8-K2023-06-270000950170-23-030186Item 5.07 · say-on-pay result. As reported: —. Filing ↗
84Section 06, 2022 voteForm 8-K2022-06-240001193125-22-181616Item 5.07 · say-on-pay result. As reported: —. Filing ↗
85Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
86Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
87Section 09b board cost (computed)Computed——Cash 162,785 + equity 109,107 + all other 0 = 271,892, summed across the director compensation table rows.machine: formula: Σ = 271,892
88Gilead Sciences, Section 10b CEO totalDEF 14A2026-03-200001308179-26-000106CEO total compensation as printed in Gilead Sciences's own proxy. As printed: 28,437,198. Filing ↗machine: t414 · r1 · c29 · span 989582–989592
89Pfizer, Section 10b CEO totalDEF 14A2026-03-120000078003-26-000033CEO total compensation as printed in Pfizer's own proxy. As printed: 27,585,301. Filing ↗machine: t242 · r3 · c12 · span 1506825–1506835
90Bristol-Myers Squibb, Section 10b CEO totalDEF 14A2026-03-250000014272-26-000006CEO total compensation as printed in Bristol-Myers Squibb's own proxy. As printed: 21,879,919. Filing ↗machine: t168 · r3 · c15 · span 1302160–1302170
91Merck & Co., Section 10b CEO totalDEF 14A2026-04-080001193125-26-147704CEO total compensation as printed in Merck & Co.'s own proxy. As printed: 20,797,845. Filing ↗machine: span 1371012–1371022
92IGM Biosciences (subject), Section 10b CEO totalDEF 14A2024-04-260000950170-24-049091CEO total compensation as printed in IGM Biosciences's own proxy. As printed: 3,207,328. Filing ↗machine: r2 · c21 · span 824822–824831
93Section 10a, Gilead Sciences reciprocityDEF 14A—0001308179-26-000106Gilead Sciences's most recent proxy was read; its disclosed peer group does not include IGM Biosciences. Filing ↗
94Section 10a, Pfizer reciprocityDEF 14A—0000078003-26-000033Pfizer's most recent proxy was read; its disclosed peer group does not include IGM Biosciences. Filing ↗
95Section 10a, Merck & Co. reciprocityDEF 14A—0001193125-26-147704Merck & Co.'s most recent proxy was read; its disclosed peer group does not include IGM Biosciences. Filing ↗
96Section 10a, Bristol-Myers Squibb reciprocityDEF 14A—0000014272-26-000006Bristol-Myers Squibb's most recent proxy was read; its disclosed peer group does not include IGM Biosciences. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.